---

Background and purpose: Ascorbic acid is an important antioxidant and its depletion is a risk factor for periodontal diseases. This study aimed to evaluate the effect of 2% atorvastatin dentifrice and ascorbic acid on improving clinical periodontal parameters in patients with chronic periodontitis.
Materials and methods: This clinical trial included 72 patients with moderate and severe chronic periodontitis attending periodontology department in Yazd Dental School, Iran. They were randomly divided into four groups (n=18 per group). Group 1 was the control group that used 0.2% fluoride dentifrice after Scaling and Root Planing (SRP). Group 2 used 0.2% flouride dentifrice + adjunctive use of atorvastatin 2% following SRP. Group 3 used 0.2% fluoride dentifrice and 250mg chewable ascorbic acid tablet after SRP. Group 4 used 0.2% fluoride dentifrice + adjunctive use of atorvastatin 2% and 250mg chewable ascorbic acid after SRP. Periodontal parameters including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and modified gingival index (MGI) were measured at baseline and one month after treatment. Data were analyzed in SPSS V17 applying Chi square, ANOVA, and Tukey test.
Results: After one month, significant decreases were seen in CAL (P= 0.0001) and MGI
(P= 0.029). In groups 2 and 4, the decrease in CAL was significantly higher than the control group
(P= 0.0001) and in comparison between case groups there were significant differences between groups 3 and 4 (P= 0.0001). In group 3, significant decrease was seen in MGI compared to the control group (P<0.05).
Conclusion: Combination treatment with SRP, 2% atorvastatin dentifrice and ascorbic acid is more effective in improving periodontal parameters than SRP alone.
 
(Clinical Trials Registry Number: IRCT20171015036782N5)
 

---

Background and purpose: Dental caries is one of the most common bacterial diseases in childhood. Using proper dentifrice is suggested to reduce the incidence of this disease. The aim of this study was to investigate the antimicrobial effects of different brands of children's dentifrice available in Iran’s market on Streptococcus mutans (PTCC1683) and Lactobacillus acidophilus (PTCC4356) strains.
Materials and methods: After culturing standard bacterial strains, different kids dentifrice brands, including Irox, Bath, Misswake, Colgate, Oral-B, Bencer, and Frice were prepared by distilled water in 2 mg/ml and 4 mg/ml and added to pits in cultures medium. Then, the samples were incubated at 37°C for 24-48 hours and diameter of the antibacterial inhibitory haloarchaea was reported in millimeters. T-test was used for statistical analysis.
Results: All dentifrices recorded an inhibitory haloarchaea diameter of 3-25 mm (except Bath and Irox at 2 mg/ml against S. mutans, 0 mm). The antibacterial strength of dentifrices was as follows: Oral-B> Colgate> Frice> Bencer> Misswake> Bath> Irox. At 4 mg/ml, the diameter of haloarchaea against L. acidophilus was approximately twice than that of S. mutans. The mean haloarchaea diameter was not significantly different between the control group and dentifrices at 4 mg/ml against S. mutans (P= 0.080). In other conditions, the mean diameter of haloarchaea in dentifrices was lower than that of the control group (P≤0.001).
Conclusion: In this in-vitro study, Oral-B and Colgate (sodium fluoride 500 ppm) had the highest antibacterial effect and Bath and Irox (sodium monofluorophosphate 500 ppm) had the lowest antibacterial strength against the studied microorganisms. In addition, except for Bath and Irox, other dentifrices in various concentrations had desirable antibacterial properties.